When a company's revenue and earnings plunge, it's understandable if investors begin to worry about its dividend.  (NYSE: PFE) reported a 53% year-over-year decline in revenue in its latest quarter. The big drugmaker's earnings sank by 77%. 

There's also the fact that Pfizer is about to face a patent cliff that could further erode its profits. Key blockbuster products including Eliquis, Ibrance, Xeljanz, and Vyndaqel lose patent exclusivity within the next few years.  Pfizer anticipates these losses of exclusivity will negatively impact its annual revenue by roughly $17 billion per year by 2030. 

So should investors worry about Pfizer's dividend, which currently yields nearly 4.6%? I don't think so. Here's why Pfizer's high-yield dividend could be safer than you might think.

Continue reading

Source Fool.com